Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.

Lossos C, Liu Y, Kolb KE, Christie AL, Van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, Nguyen QD, Craig JW, Morgan EA, Vega F, Aster JC, Sarosiek KA, Shalek AK, Hemann MT, Weinstock DM.

Cancer Discov. 2019 Apr 30. doi: 10.1158/2159-8290.CD-18-1393. [Epub ahead of print]

PMID:
31040105
2.

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.

Singh R, Letai A, Sarosiek K.

Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193. doi: 10.1038/s41580-018-0089-8. Review.

PMID:
30655609
3.

T Cells and Regulated Cell Death: Kill or Be Killed.

Spetz J, Presser AG, Sarosiek KA.

Int Rev Cell Mol Biol. 2019;342:27-71. doi: 10.1016/bs.ircmb.2018.07.004. Epub 2018 Aug 29.

PMID:
30635093
4.

BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies.

Fraser C, Ryan J, Sarosiek K.

Methods Mol Biol. 2019;1877:61-76. doi: 10.1007/978-1-4939-8861-7_4.

PMID:
30535998
5.

Getting the Most Out of Augmentation-Mastopexy.

Sarosiek K, Maxwell GP, Unger JG.

Plast Reconstr Surg. 2018 Nov;142(5):742e-759e. doi: 10.1097/PRS.0000000000004961. Review.

PMID:
30511991
6.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
7.

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.

McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr.

Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13.

PMID:
30220459
8.

Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment.

Spetz J, Moslehi J, Sarosiek K.

Curr Treat Options Cardiovasc Med. 2018 Mar 20;20(4):31. doi: 10.1007/s11936-018-0627-x. Review.

PMID:
29556748
9.

Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage.

Gutierrez-Martinez P, Hogdal L, Nagai M, Kruta M, Singh R, Sarosiek K, Nussenzweig A, Beerman I, Letai A, Rossi DJ.

Nat Cell Biol. 2018 Apr;20(4):413-421. doi: 10.1038/s41556-018-0054-y. Epub 2018 Mar 12.

10.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.

Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.

11.

Epigenetics make transient states of cancer therapy resistance permanent.

Sarosiek K.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaan6729. doi: 10.1126/scitranslmed.aan6729.

PMID:
28659441
12.

Chemotherapy-treated cells go up in flames.

Sarosiek K.

Sci Transl Med. 2017 May 17;9(390). pii: eaan4289. doi: 10.1126/scitranslmed.aan4289.

PMID:
28515339
13.

Incidence and Risk Factors for Major Hematomas in Aesthetic Surgery: Analysis of 129,007 Patients.

Kaoutzanis C, Winocour J, Gupta V, Ganesh Kumar N, Sarosiek K, Wormer B, Tokin C, Grotting JC, Higdon KK.

Aesthet Surg J. 2017 Oct 16;37(10):1175-1185. doi: 10.1093/asj/sjx062.

PMID:
28398469
14.

Double trouble for CML.

Sarosiek K.

Sci Transl Med. 2017 Apr 5;9(384). pii: e2773. doi: 10.1126/scitranslmed.aan2773.

PMID:
28381535
15.

Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.

Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S.

Cancer Lett. 2017 Jun 1;395:1-10. doi: 10.1016/j.canlet.2017.02.028. Epub 2017 Mar 1.

PMID:
28259821
16.

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.

Le Pen J, Maillet L, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou JC, Letaï A, Braun F, Juin PP.

Cell Death Dis. 2017 Feb 9;8(2):e2596. doi: 10.1038/cddis.2016.127. No abstract available.

17.

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A.

Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub 2016 Dec 22.

18.

Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.

Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SWG, Gautier F, Juin PP.

Cell Rep. 2016 Dec 20;17(12):3347-3358. doi: 10.1016/j.celrep.2016.11.064.

19.

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.

Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.

20.

Interleukin 21 - its potential role in the therapy of B-cell lymphomas.

Bhatt S, Sarosiek KA, Lossos IS.

Leuk Lymphoma. 2017 Jan;58(1):17-29. Epub 2016 Jul 13. Review.

PMID:
27405876
21.

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ.

Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.

22.

Hypothyroidism in Pancreatic Cancer: Role of Exogenous Thyroid Hormone in Tumor Invasion-Preliminary Observations.

Sarosiek K, Gandhi AV, Saxena S, Kang CY, Chipitsyna GI, Yeo CJ, Arafat HA.

J Thyroid Res. 2016;2016:2454989. doi: 10.1155/2016/2454989. Epub 2016 Mar 31.

23.
24.

Conserved Metabolic Changes in Nondiabetic and Type 2 Diabetic Bariatric Surgery Patients: Global Metabolomic Pilot Study.

Sarosiek K, Pappan KL, Gandhi AV, Saxena S, Kang CY, McMahon H, Chipitsyna GI, Tichansky DS, Arafat HA.

J Diabetes Res. 2016;2016:3467403. doi: 10.1155/2016/3467403. Epub 2016 Jan 10.

25.

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.

Le Pen J, Maillet L, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou JC, Letaï A, Braun F, Juin PP.

Cell Death Dis. 2016 Feb 4;7:e2083. doi: 10.1038/cddis.2015.400. Erratum in: Cell Death Dis. 2017 Feb 9;8(2):e2596.

26.

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS.

Blood. 2015 Sep 24;126(13):1555-64. doi: 10.1182/blood-2015-01-624585. Epub 2015 Jul 20.

27.

An approach to the diagnosis and treatment of gastrointestinal bleeding secondary to jejunal diverticulosis.

Moukarzel LA, Sarosiek K, Kang C, Krazwitz S, Loren D, Pucci MJ.

Am Surg. 2015 Mar;81(3):E93-5. No abstract available.

PMID:
25760177
28.

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.

Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042.

29.

Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Sarosiek K, Jones E, Chipitsyna G, Al-Zoubi M, Kang C, Saxena S, Gandhi AV, Sendiky J, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2015 Apr;19(4):639-50. doi: 10.1007/s11605-014-2735-6. Epub 2015 Jan 13.

PMID:
25583441
30.

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra122. doi: 10.1126/scisignal.2005301.

31.

Perioperative use of the imacor hemodynamic transesophageal echocardiography probe in cardiac surgery patients: initial experience.

Sarosiek K, Kang CY, Johnson CM, Pitcher H, Hirose H, Cavarocchi NC.

ASAIO J. 2014 Sep-Oct;60(5):553-8. doi: 10.1097/MAT.0000000000000113.

PMID:
25010912
32.

RAN GTPase and Osteopontin in Pancreatic Cancer.

Saxena S, Gandhi A, Lim PW, Relles D, Sarosiek K, Kang C, Chipitsyna G, Sendecki J, Yeo CJ, Arafat HA.

Pancreat Disord Ther. 2013 Apr 1;3(1):113.

33.

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA.

Cancer Res. 2014 Jun 1;74(11):3146-56. doi: 10.1158/0008-5472.CAN-13-3728. Epub 2014 Mar 27.

34.

Ad hoc cost analysis of the new gastrointestinal bleeding algorithm in patients with ventricular assist device.

Hirose H, Sarosiek K, Cavarocchi NC.

ASAIO J. 2014 May-Jun;60(3):351-2. doi: 10.1097/MAT.0000000000000052.

PMID:
24469295
35.

Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.

Al-Zoubi M, Chipitsyna G, Saxena S, Sarosiek K, Gandhi A, Kang CY, Relles D, Andrelsendecki J, Hyslop T, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2014 Feb;18(2):257-68; discussion 268. doi: 10.1007/s11605-013-2370-7. Epub 2013 Oct 4.

PMID:
24091913
36.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

37.

BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A.

Mol Cell. 2013 Sep 26;51(6):751-65. doi: 10.1016/j.molcel.2013.08.048.

38.

Mitochondria: gatekeepers of response to chemotherapy.

Sarosiek KA, Ni Chonghaile T, Letai A.

Trends Cell Biol. 2013 Dec;23(12):612-9. doi: 10.1016/j.tcb.2013.08.003. Epub 2013 Sep 21. Review.

39.

Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.

Kang CY, Wang J, Axell-House D, Soni P, Chu ML, Chipitsyna G, Sarosiek K, Sendecki J, Hyslop T, Al-Zoubi M, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2014 Jan;18(1):7-15. doi: 10.1007/s11605-013-2326-y. Epub 2013 Sep 4.

PMID:
24002763
40.

Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma.

Gandhi AV, Saxena S, Relles D, Sarosiek K, Kang CY, Chipitsyna G, Sendecki JA, Yeo CJ, Arafat HA.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S636-43. doi: 10.1245/s10434-013-3128-x. Epub 2013 Jul 12.

PMID:
23846787
41.

An old problem with a new therapy: gastrointestinal bleeding in ventricular assist device patients and deep overtube-assisted enteroscopy.

Sarosiek K, Bogar L, Conn MI, O'Hare B, Hirose H, Cavarocchi NC.

ASAIO J. 2013 Jul-Aug;59(4):384-9. doi: 10.1097/MAT.0b013e318299fcd3.

PMID:
23820277
42.

Adult extracorporeal membrane oxygenation and gastrointestinal bleeding from small bowel arteriovenous malformations: a novel treatment using spiral enteroscopy.

Sarosiek K, Hirose H, Pitcher HT, Cavarocchi NC.

J Thorac Cardiovasc Surg. 2012 May;143(5):1221-2. doi: 10.1016/j.jtcvs.2011.10.067. Epub 2011 Dec 3. No abstract available.

43.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A.

Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27.

44.

HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway.

Jiang X, Lu X, McNamara G, Liu X, Cubedo E, Sarosiek KA, Sánchez-García I, Helfman DM, Lossos IS.

Blood. 2010 Dec 9;116(24):5217-27. doi: 10.1182/blood-2010-04-281568. Epub 2010 Sep 15.

45.

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13069-74. doi: 10.1073/pnas.1002985107. Epub 2010 Jul 6.

46.

Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.

Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS.

Blood. 2010 Jan 21;115(3):570-80. doi: 10.1182/blood-2009-08-239996. Epub 2009 Nov 20.

47.

Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.

Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS.

Br J Haematol. 2009 Nov;147(3):308-18. doi: 10.1111/j.1365-2141.2009.07851.x. Epub 2009 Aug 19.

48.

Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.

Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, Tibshirani R, Lossos IS.

Blood. 2009 Apr 16;113(16):3754-64. doi: 10.1182/blood-2008-10-184077. Epub 2008 Dec 1.

49.

PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.

Lu X, Malumbres R, Shields B, Jiang X, Sarosiek KA, Natkunam Y, Tiganis T, Lossos IS.

Blood. 2008 Nov 15;112(10):4098-108. doi: 10.1182/blood-2008-03-148726. Epub 2008 Aug 20.

50.

T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.

Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS.

Mol Cell Biol. 2007 Mar;27(6):2166-79. Epub 2007 Jan 8.

Supplemental Content

Loading ...
Support Center